Podcast

Advancing Precision Oncology With the Syapse Precision Medicine Council

In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council.

In June, Syapse—a company that works with health systems to implement precision medicine across its organizations—took the next step in leading the shift toward precision medicine by launching the Syapse Precision Medicine Council. The council consists of oncology, operations, and research leaders from health systems dedicated to advancing precision medicine through sharing strategies and insights in order to identify best practices.

Dennis Shin, chief commercial officer of Syapse, discussed the formation of the council, how it plans to disrupt the current precision oncology landscape, and what he sees for the future of the council.

To listen, login to the website.

Listen above or through one of these podcast services:

iTunes: http://apple.co/2eYWTss?rel=0"

TuneIn: http://bit.ly/2gv7iwj?rel=0"

Stitcher: http://bit.ly/2gCqtFg?rel=0"

Syapse, Roche Team Up to Advance Precision Medicine in Oncology

Syapse Looks to Expand Precision Medicine Partnerships With New CEO

Oncologists Are Crucial to Advancing Precision Medicine

Precision Health AI Launches Platform to Deliver Data-Driven Insights in Oncology

Using Health IT to Increase Medication Adherence and Enhance Precision Medicine

Read more about Syapse and precision oncology:

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
Benjamin Scirica, MD, MPH, associate professor of medicine at Harvard Medical School and director of quality initiatives at Brigham and Women’s Hospital’s Cardiovascular Division
dr andrew leitner
Laurence Sperling, MD
Glenn Balasky during a video interview
Related Content
Non-Hodgkin Lymphoma | Image Credit: © MQ-Illustrations - stock.adobe.com
November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser
Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
FDA Approval-BHM-stock.adobe.com
November 14th 2024

FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions

Giuliana Grossi
The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
managed care cast logo
October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
AJMC
November 13th 2024

How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care

Arthur S. Hong, MD, MPH Beverly Kyalwazi, MD Ethan A. Halm, MD, MPH, MBA D. Mark Courtney, MD, MSCI John W. Sweetenham, MD Navid Sadeghi, MD, MSPH John V. Cox, DO, MBA Simon J. Craddock Lee, PhD, MPH
Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Lindsay Bealor Greenleaf, JD, MBA | Image credit: ADVI Health
November 12th 2024

The Trump Sequel: What to Expect on PBMs, 340B, Drug Pricing, and RFK Jr

Interview by Mary Caffrey
Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of the election.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo